Thomas J Tucker
Overview
Explore the profile of Thomas J Tucker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johns D, Campeau L, Banka P, Bautmans A, Bueters T, Bianchi E, et al.
Circulation
. 2023 May;
148(2):144-158.
PMID: 37125593
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2...
2.
Tucker T, Embrey M, Alleyne C, Amin R, Bass A, Bhatt B, et al.
J Med Chem
. 2021 Oct;
64(22):16770-16800.
PMID: 34704436
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. Starting from...
3.
Simov V, Altman M, Bianchi E, DelRizzo S, DiNunzio E, Feng G, et al.
Eur J Med Chem
. 2021 Jul;
224:113686.
PMID: 34303079
Pathway activating mutations of the transcription factor NRF2 and its negative regulator KEAP1 are strongly correlative with poor clinical outcome with pemetrexed/carbo(cis)platin/pembrolizumab (PCP) chemo-immunotherapy in lung cancer. Despite the strong...
4.
Alleyne C, Amin R, Bhatt B, Bianchi E, Blain J, Boyer N, et al.
J Med Chem
. 2020 Nov;
63(22):13796-13824.
PMID: 33170686
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. In this...
5.
Gelenter M, Smith K, Liao S, Mandala V, Dregni A, Lamm M, et al.
Nat Struct Mol Biol
. 2019 Jun;
26(7):592-598.
PMID: 31235909
Glucagon and insulin maintain blood glucose homeostasis and are used to treat hypoglycemia and hyperglycemia, respectively, in patients with diabetes. Whereas insulin is stable for weeks in its solution formulation,...
6.
Algayer B, OBrien A, Momose A, Murphy D, Procopio W, Tellers D, et al.
Molecules
. 2019 Jun;
24(11).
PMID: 31159194
Delivery of macromolecular cargos such as siRNA to the cytosol after endocytosis remains a critical challenge. Numerous approaches including viruses, lipid nanoparticles, polymeric constructs, and various peptide-based approaches have yet...
7.
Parmentier-Batteur S, Hutson P, Menzel K, Uslaner J, Mattson B, OBrien J, et al.
Neuropharmacology
. 2013 Jan;
82:161-73.
PMID: 23291536
Previous work has suggested that activation of mGlu5 receptor augments NMDA receptor function and thereby may constitute a rational approach addressing glutamate hypofunction in schizophrenia and a target for novel...
8.
Aaronson J, Klein L, Momose A, OBrien A, Shaw A, Tucker T, et al.
Bioconjug Chem
. 2011 Jul;
22(8):1723-8.
PMID: 21744777
Conditions for facile solution-phase amide conjugation of amine-modified siRNA with a diverse set of carboxylic acid partners using the coupling reagent HATU are described. These conditions eliminate the need for...
9.
Lai M, Lu M, Felock P, Hrin R, Wang Y, Yan Y, et al.
Antimicrob Agents Chemother
. 2010 Sep;
54(11):4812-24.
PMID: 20805392
Studies were conducted to investigate mutation pathways among subtypes A, B, and C of human immunodeficiency virus type 1 (HIV-1) during resistance selection with nonnucleoside reverse transcriptase inhibitors (NNRTIs) in...
10.
Su D, Lim J, Tinney E, Tucker T, Saggar S, Sisko J, et al.
Bioorg Med Chem Lett
. 2010 Jul;
20(15):4328-32.
PMID: 20609585
Biaryl ethers were recently reported as potent NNRTIs. Herein, we disclose a detailed effort to modify the previously reported compound 1. We have designed and synthesized a series of novel...